-14.0% · 90d
$1.72
+0.00 (+0.00%)
After-Hours $1.75(+0.03)
News
(1)April 2026
Cardiff Oncology Proposes Adding 3 Million Shares to Employee Compensation Plan
CRDFCardiff Oncology, Inc.
# 🧾 What This Document Is This is a **DEF 14A**, also known as a **Proxy Statement**. Cardiff Oncology is sending this to its shareholders ahead of the annual meeting to explain what will be voted on and provide important company information. Think of it as an agenda and info packet for the company
Read summaryView on SEC EDGAR
Peers in Biotechnology
VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%